News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Microbicides
First Multipurpose Gel Designed to Prevent HIV, HSV, and HPV Simultaneously in Women and Men Advances in Clinical Trials

A new Phase I study of the Population Council’s multipurpose prevention technology (MPT) gel PC-1005, launching this week, will examine the safety of the gel when used rectally by both men and women. If proven effective, PC-1005 gel would be the first product to prevent three incurable sexually transmitted infections (STIs)—HIV, herpes simplex virus (HSV), and human papillomavirus (HPV)—when used either vaginally or rectally.

Published
25 June 2018
From
Population Council
PrEP
Vaginal implant might stop HIV transmission

Scientists at the University of Waterloo have developed a promising new medical device that could help protect women from HIV. The technology consists of a vaginal implant that basically reduces the amount of targets the virus can latch onto during sex, and may prove a more effective measure than some anti-HIV drugs or condoms in fending off infections.

Published
17 April 2018
From
New Atlas
Transmission and prevention
CROI 2018: Highlights and what’s next for advocates

Historically, CROI is heavy on basic science and early-phase research. Data from these types of studies were still prominent in 2018, but this year the meeting also broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.

Published
27 March 2018
From
AVAC
Microbicides
The vaginal ring: more HOPE to the DREAM? Higher adherence and better effectiveness seen in open-label ring studies

Two open-label, parallel studies of vaginal rings used to prevent HIV in women released interim results at the 25th Conference on Retroviruses and Opportunistic Infections (CROI

Published
08 March 2018
By
Gus Cairns
Microbicides
In the Era of Daily PrEP, Feds May Stop Research Funding Gels, Rings, and Douches for HIV Prevention

It's precisely because of the overwhelming success in recent years of oral PrEP that the future of the anal douche and other sorts of topically applied anti-HIV agents, such as gels and dissolvable films, all loosely termed "microbicides," is suddenly up in the air, if not outright doomed.

Published
07 March 2018
From
The Body
Microbicides
Genital inflammation reduces efficacy of tenofovir gel against HIV in women

The researchers performed a post hoc prospective analysis of 774 patients who participated in the Centre for the AIDS Program of Research In South Africa (CAPRISA) 004 study, a trial of topical tenofovir gel. McKinnon and colleagues measured concentrations of nine different proinflammatory cytokines from cervicovaginal lavages, and defined genital inflammation using a graduated cytokine store.

Published
28 February 2018
From
Healio
Microbicides
Do HIV-Preventing Microbicides Have a Future in the Age of PrEP?

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

Published
11 December 2017
From
Poz
Microbicides
Vital Microbicides May Soon Be Out of Reach

Whether, when, and how microbicide development proceeds depends on the U.S government, and the federal Division of AIDS has suggested this development may no longer be a priority. It's wrong.

Published
10 November 2017
From
Rewire
Microbicides
DAIDS Boss Muses on the Future of HIV Prevention Research

Below are some of Dr. Dieffenbach’s rather intentionally provocative ideas about specific HIV prevention research candidates—challenges and promises, and the questions they may raise for the next clinical trial research network structure.

Published
20 October 2017
From
AVAC
Microbicides
Population Council Advances Non-Antiretroviral Multipurpose Prevention Technology For HIV and STI Prevention to Clinical Trial

First in-human clinical trial of griffithsin, a naturally occurring anti-HIV protein, which limits risk of cross-resistance to antiretroviral (ARV) products.

Published
16 October 2017
From
Population Council
← Prev12345...26Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.